Aclarion (ACON) vs Exagen (XGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Exagen is the larger company by market cap ($92.1 million vs $3.5 million), about 26.1 times the size, while Aclarion is growing revenue faster (+65.6% vs +19.7%). Exagen converts more of its revenue into profit, with a net margin of -30.0% versus -9551.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACON | XGN |
|---|---|---|
| Share price | $1.22 | $3.61 |
| Market cap | $3.52M | $92.10M |
| 1-day change | -13.92% | -5.00% |
| YTD return | — | -40.63% |
| 1-year return | — | -52.56% |
| 5-year return | — | -67.24% |
| EPS (TTM) | $-5.01 | $-0.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $75.73K | $66.58M |
| Revenue growth (YoY) | +65.62% | +19.65% |
| Net income (latest FY) | $-7.23M | $-19.95M |
| Gross margin | 9.02% | 58.28% |
| Operating margin | -9312.55% | -21.13% |
| Net margin | -9551.87% | -29.97% |
| 52-week high | $9.36 | $9.22 |
| 52-week low | $1.22 | $2.59 |
| Distance from 52-week high | -86.94% | -60.85% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +524.18% | +185.04% |
| Average volume | 34.73K | 470.43K |
| Shares outstanding | 2.88M | 25.51M |
| Employees | 10 | 216 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Exagen is about 26.1 times larger than Aclarion by market value ($92.10M vs $3.52M).
- Exagen is more profitable, keeping -30.0 cents of every revenue dollar as net income versus -9551.9 cents for Aclarion.
- Aclarion grew revenue faster in its latest fiscal year (+65.62% vs +19.65%).
About Aclarion
ACON stock →Aclarion, Inc. operates as a healthcare technology company in the United States.
Health Care · Medical Specialities · 10 employees
About Exagen
XGN stock →Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States.
Health Care · Medical Specialities · 216 employees
ACON vs XGN FAQ
Which is bigger, Aclarion or Exagen?
Exagen (XGN) is larger, with a market capitalization of $92.10M compared with $3.52M for Aclarion (ACON).
Are Aclarion and Exagen in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.